Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.03.29.014407: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Cells, virus and antivirals: Vero E6 (Vero C1008, clone E6 – CRL-1586; ATCC) cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with non-essential amino acids (NEAA), penicillin/streptomycin (P/S), Hepes buffer and 10% (v/v) Fetal bovine serum (FBS). Vero C1008suggested: ATCC Cat# CRL-1586, RRID:CVCL_0574)A clinical isolate hCoV-19/Italy/UniSR1/2020 (GISAID accession ID: EPI_ISL_413489) was isolated and … SciScore for 10.1101/2020.03.29.014407: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Experimental Models: Cell Lines Sentences Resources Cells, virus and antivirals: Vero E6 (Vero C1008, clone E6 – CRL-1586; ATCC) cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with non-essential amino acids (NEAA), penicillin/streptomycin (P/S), Hepes buffer and 10% (v/v) Fetal bovine serum (FBS). Vero C1008suggested: ATCC Cat# CRL-1586, RRID:CVCL_0574)A clinical isolate hCoV-19/Italy/UniSR1/2020 (GISAID accession ID: EPI_ISL_413489) was isolated and propagated in Vero E6 cells, and viral titer was determined by 50% tissue culture infective dose (TCID50) and plaque assay for confirming the obtained titer. Vero E6suggested: NoneSoftware and Algorithms Sentences Resources The quality of raw sequences obtained from MiSeq run was first checked using FastQC (v 0.11.5) (Babraham Bioinformatics). MiSeqsuggested: (A5-miseq, RRID:SCR_012148)FastQCsuggested: (FastQC, RRID:SCR_014583)The reads were aligned on reference sequence (GISAID accession ID: EPI_ISL_412973) using BWA-mem and rescued using Samtools alignment/Map (v 1.9) and bamtoFastq. BWA-memsuggested: (Sniffles, RRID:SCR_017619)Samtoolssuggested: (SAMTOOLS, RRID:SCR_002105)Finally, the contigs were generated using SPAdes (v 3.12.0). SPAdessuggested: (SPAdes, RRID:SCR_000131)Then, two-way ANOVA and Tukey’s multiple comparisons test were performed for the evaluation of Ct differences (GraphPad Prism 8). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
- No funding statement was detected.
- No protocol registration statement was detected.
-